| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
ORIGINAL ARTICLE |
Department of Human Pathology and Oncology, University of Florence Medical School, Viale G.B. Morgagni, 85, 50134 Florence, Italy
Correspondence to:
Professor C E Comin
Department of Human Pathology and Oncology, University of Florence Medical School, Viale G.B. Morgagni, 85, 50134 Firenze, Italia; camilla.comin{at}unifi.it
Aims: To compare intratumorous microvessel density (MVD) and clinicopathological features in two different groups of hepatocellular carcinoma (HCC), namely: hepatitis B virus (HBV) related HCC (B-HCC) and HCV related HCC (C-HCC).
Methods: Fifty consecutive cases each of B-HCC and of C-HCC were studied. Microvessel numbers were assessed by staining for the antigen CD34; in each case, three areas with the highest numbers of microvessels were counted in both the intratumorous and the surrounding non-tumorous tissue; the mean value represented the final MVD.
Results: Patients with B-HCC were significantly younger than those with C-HCC (mean age, 60.1 (SD, 4.1) v 66.4 (4.3) years); no significant differences were seen for sex or Child’s class distribution. The tumour diameter was larger in B-HCCs than in C-HCCs (mean, 5.6 (SD, 1.8) v 3.8 (1.8) cm). Tumour microsatellite formation was significantly higher in C-HCCs (12 v 4 cases). No differences were found for histological subtype, degree of differentiation, tumour encapsulation, and vascular invasion. The mean MVD value was significantly higher in tumorous (mean, 54 (SD, 13.8) v 38 (8.9)) and in the surrounding non-tumorous liver tissue (mean, 15 (SD, 4.3) v 7 (3.1)) of C-HCCs.
Conclusions: C-HCCs present as smaller tumours in older patients, with a higher incidence of tumour microsatellite formation and higher MVD values both in the tumorous and the non-tumorous areas, suggesting a link between HCV infection, angiogenesis, and hepatocarcinogenesis.
Abbreviations: B-HCC, hepatitis B virus hepatocellular carcinoma; C-HCC, hepatitis C virus related hepatocellular carcinoma; COX-2, cyclooxygenase-2; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; iNOS, inducible nitric oxide synthase; MVD, microvessel density; PD-ECGF, platelet derived endothelial cell growth factor
Keywords: microvessel density; hepatitis C virus; hepatitis B virus; hepatocellular carcinoma
This article has been cited by other articles:
|
|
 |
|
  A. X. Zhu, N. S. Holalkere, A. Muzikansky, K. Horgan, and D. V. Sahani Early Antiangiogenic Activity of Bevacizumab Evaluated by Computed Tomography Perfusion Scan in Patients with Advanced Hepatocellular Carcinoma Oncologist, February 1, 2008; 13(2): 120 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Michaelis, R. Michaelis, T. Suhan, H. Schmidt, A. Mohamed, H. W. Doerr, and J. Cinatl Jr. Ribavirin inhibits angiogenesis by tetrahydrobiopterin depletion FASEB J, January 1, 2007; 21(1): 81 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. X. Zhu, L. S. Blaszkowsky, D. P. Ryan, J. W. Clark, A. Muzikansky, K. Horgan, S. Sheehan, K. E. Hale, P. C. Enzinger, P. Bhargava, et al. Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma J. Clin. Oncol., April 20, 2006; 24(12): 1898 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. X. Zhu, C. S. Fuchs, J. W. Clark, A. Muzikansky, K. Taylor, S. Sheehan, K. Tam, E. Yung, M. H. Kulke, and D. P. Ryan A Phase II Study of Epirubicin and Thalidomide in Unresectable or Metastatic Hepatocellular Carcinoma Oncologist, June 1, 2005; 10(6): 392 - 398. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |
